November 17, 2009 (FinancialWire) IRIS International, Inc. (NASDAQ: IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, has appointed Lawrence J. Blecka, Ph.D., a senior executive with 30 years experience in medical device, diagnostics and biotechnology companies ranging from Fortune 500 to start-ups, as vice president, Research and Development.
Dr. Blecka will be responsible for overseeing all research and development of the Iris Diagnostics division, in support of the advancement of the companys existing and emerging product pipeline.
Prior to joining IRIS, from 1999 to 2009, Dr. Blecka was Group Engineering Manager for the BioPlex Division of Bio-Rad Laboratories, Inc. (NYSE: BIO), a multinational manufacturer and distributor of life science research and clinical diagnostic products, where he directed a team of 45 engineers for the development of its BioPlex 2200 automated immunoassay platform to analyze multiple disease markers from a single patient sample. From 1997 to 1999, he was Corporate vice president, Research and Development for Metrika, Inc., a manufacturer and marketer of multi-use disposable diabetes monitoring products, acquired by Bayer in 2006.
Before that, from 1994 to 1997, he was Corporate vice president, Product Development of Biocircuits Corp., where he directed a staff of 30 scientists and engineers and was responsible for all aspects of product development, having developed six new products and FDA 510(k) clearances within 18 months of joining the firm. From 1992 to 1994, he was vice president, Research and Development of Sigma-Aldrich, Inc., Diagnostics Division, where he led the development and launched 50 new products in two and a half years.
From 1979 to 1991, Dr. Blecka had a distinguished career with Abbott Laboratories, Diagnostics Division, where he held numerous executive positions ranging from Manager of Scientific Affairs to Manager of Regulatory Affairs to director of Research and Development and general manager of the Cancer Business Unit, where he had worldwide P&L responsibility and grew sales to $87 million from $56 million in less than two years. As director of Abbotts Probe Diagnostics Venture, he developed an automated system for nucleic acid probe assays using IMx technology, which is sold TODAY as the Abbott LCx. He also managed the development of nucleic acid probe amplification and detection assays for human papillomavirus, human immunodeficiency virus, and Chlamydia, among others.
Blecka began his career in 1972 at the University of Illinois, Medical Schools in Chicago, Illinois, as Assistant Professor and Technical director Hospital Clinical Laboratory. From 1972 through 1982, he was a faculty member of the Graduate College Faculty, College of Medicine, and College of Allied Health and Medicine, University of Illinois, responsible for conducting research and teaching courses in clinical chemistry, parasitology and medical microbiology.
Blecka earned a bachelor of arts in biology from Lewis University, in 1966, a master of arts in biology (with an emphasis in molecular biology) from Northern Illinois University in 1967, and earned his doctorate in microbiology/zoology, from Southern Illinois University in 1972.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
Free annual reports, filings and conference call webcasts for companies mentioned in the news are available via Investrend Syndications (http://investrend.ar.wilink.com/?level=279). Mondays issued reports and/or recorded webcasts include Marine Harvest ASA (x: MHG), China GengSheng Minerals, Inc. (OTCBB: CHGS), Skystar Bio-Pharmaceutical Company (OTCBB: SKBI), Fortuna Silver Mines, Inc. (TSX Venture: FVI), LocatePLUS Holdings, Inc. (OTC: LPHC) and Premier Power Renewable Energy, Inc. (OTCBB: PPRW).
IRIS International To Host Financial Analysts, Fund Managers December 16, 2009 (FinancialWire) IRIS International, Inc. (NASDAQ: IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories... |
Gala-Net, Inc. to Publish Iris Online in the North American Market Gala-Net, Inc., the leading free-to-play online game publisher, has announced today their continued partnership with EYA SOFT Co. Ltd. to publish Iris in the North American market."EYA is delighted to... |
How the Eye Works SAN FRANCISCO, CA, October 03, 2009 /24-7PressRelease/ -- The human eye is truly a miracle of engineering, making it possible to see objects at a wide variety of distances, and working in perfect harmony... |
GrowthGate Acquires Part of Leading Iris Biometric Company ‘IrisGuard Inc.’ Mar 9, 2010 (PRN): GrowthGate, the GCC-based specialist buyout firm, announced that it has reached a final agreement to acquire 30% of IrisGuard, a world leader in iris recognition technologies (IRT).... |
IRIS Internationals Sample Processing Division Enters Veterinary Ova and Parasite Detection Market November 18, 2009 (FinancialWire) The IRIS International, Inc. (NASDAQ: IRIS) Sample Processing Division has initiated shipments of its new StatSpin(R) OvaTube System for use in veterinary hospitals,... |
Heska Inks Supply Deal With Roche November 27, 2009 (FinancialWire) Heska Corp. (NASDAQ: HSKA), a provider of diagnostic and specialty products to the veterinary industry, has inked agreements with Roche Diagnostics Corp. for the supply... |
